Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Time-Restricted eating: a simple diet hack for weight loss?

NCT ID NCT04916730

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether limiting food intake to a 10-hour window each day helps obese adults lose weight and improve body composition. Sixty-one participants will either follow this eating pattern plus nutritional counseling, or just receive counseling alone. The goal is to see if time-restricted eating is a practical, effective tool for weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
time-restricted eating (10-hour eating window)
What this could lead to
If it works, this could offer a simple, drug-free way to help manage obesity and improve body composition.
What could go wrong
This is a small, early-stage study with only 61 participants. Results may not apply to everyone, and sticking to a strict eating window can be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Dec 2020

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: ≥ 18 years old 2. BMI 30-50 kg/m2 3. Own a smartphone with Apple iOS or Android OS 4. Baseline eating window ≥ 14 hours/day 5. If patients are on cardiovascular medications (HMG CoA reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive drugs, no dose adjustments will be allowed during the study period. Exclusion Criteria: 1. Taking insulin or anti-diabetic medications within the last 6 months. 2. Manifest diabetes, defined as fasting glucose ≥ 126 mg/dL, HbA1c ≥ 6.5%, or diagnosis of diabetes. 3. Currently taking any medication that is meant for, or has known effect on, appetite or body weight 4. Pregnant or breast-feeding women. 5. Caregiver for a dependent requiring frequent nocturnal care/sleep interruptions. Shift workers with variable (e.g. nocturnal) hours. 6. Planned international travel (time zone changes) during study period. 7. Taking therapeutic anticoagulation which might increase risk of bleeding from adipose tissue biopsy 8. History of surgical intervention for weight loss. 9. History of eating disorder 10. Currently enrolled in a weight-loss or weight-management program 11. On a special or prescribed diet for other reasons (e.g. Celiac disease) 12. Known inflammatory and/or rheumatologic disease 13. Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse 14. History of bone marrow or solid organ transplant 15. History of heart failure 16. History of major adverse cardiovascular events (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, stroke/transient ischemic attack (TIA)). 17. History of atrial fibrillation or atrial flutter 18. History of malignancy, other than non-melanoma skin cancer, that is currently being treated, or that has not been treated with definitive therapy and considered to be in remission. 19. History of hypo- or hyperthyroidism requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e. hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion) 20. History of adrenal disease 21. History of cirrhosis 22. History of stage 4 or 5 chronic kidney disease or requiring dialysis 23. History of HIV/AIDS 24. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness). 25. History of obstructive sleep apnea (not on stable positive pressure therapy or other treatment for at least 3 months prior to enrollment) 26. Abnormal screening labs: renal dysfunction (eGFR \< 30 ml/min/1.73 m2), anemia, hypo- or hyperthyroidism, coagulopathy, abnormal liver function (AST, ALT \> 3x upper limit of normal)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fasting Intermittent Fasting Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Altman Clinical and Translational Research Institute

    La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.